$1.47 EPS Expected for Charles River Laboratories Intl. Inc (CRL) This Quarter

Brokerages expect Charles River Laboratories Intl. Inc (NYSE:CRL) to announce earnings per share (EPS) of $1.47 for the current fiscal quarter, according to Zacks Investment Research. Seven analysts have provided estimates for Charles River Laboratories Intl.’s earnings. The lowest EPS estimate is $1.45 and the highest is $1.52. Charles River Laboratories Intl. posted earnings per share of $1.29 in the same quarter last year, which would suggest a positive year-over-year growth rate of 14%. The company is scheduled to announce its next quarterly earnings report on Wednesday, August 8th.

According to Zacks, analysts expect that Charles River Laboratories Intl. will report full-year earnings of $5.82 per share for the current financial year, with EPS estimates ranging from $5.73 to $5.90. For the next year, analysts forecast that the firm will post earnings of $6.52 per share, with EPS estimates ranging from $6.41 to $6.60. Zacks’ earnings per share averages are an average based on a survey of research analysts that follow Charles River Laboratories Intl..

Charles River Laboratories Intl. (NYSE:CRL) last released its quarterly earnings data on Thursday, May 10th. The medical research company reported $1.38 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.26 by $0.12. The business had revenue of $493.97 million during the quarter, compared to analysts’ expectations of $480.03 million. Charles River Laboratories Intl. had a net margin of 6.78% and a return on equity of 24.96%. The firm’s quarterly revenue was up 10.8% compared to the same quarter last year. During the same period in the prior year, the company earned $1.29 EPS.

Several brokerages have issued reports on CRL. TheStreet upgraded shares of Charles River Laboratories Intl. from a “c+” rating to a “b+” rating in a research report on Thursday, May 10th. Zacks Investment Research upgraded shares of Charles River Laboratories Intl. from a “hold” rating to a “buy” rating and set a $117.00 price target for the company in a research report on Friday, May 11th. SunTrust Banks upgraded shares of Charles River Laboratories Intl. from a “hold” rating to a “buy” rating and upped their price target for the company from $107.66 to $125.00 in a research report on Wednesday, February 14th. Robert W. Baird set a $123.00 price target on shares of Charles River Laboratories Intl. and gave the company a “buy” rating in a research report on Tuesday, February 13th. Finally, Morgan Stanley restated an “equal weight” rating and issued a $102.00 price target (up from $94.00) on shares of Charles River Laboratories Intl. in a research report on Wednesday, March 14th. Nine investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Charles River Laboratories Intl. presently has an average rating of “Buy” and an average price target of $115.86.

In other news, Director George Massaro sold 1,218 shares of the company’s stock in a transaction on Monday, May 14th. The shares were sold at an average price of $107.19, for a total value of $130,557.42. Following the sale, the director now directly owns 15,055 shares of the company’s stock, valued at approximately $1,613,745.45. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO James C. Foster sold 24,008 shares of the company’s stock in a transaction on Tuesday, March 6th. The shares were sold at an average price of $110.00, for a total transaction of $2,640,880.00. Following the completion of the sale, the chief executive officer now directly owns 325,684 shares in the company, valued at $35,825,240. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 55,944 shares of company stock worth $6,139,665. Insiders own 2.10% of the company’s stock.

Several large investors have recently bought and sold shares of the company. Allianz Asset Management GmbH boosted its stake in shares of Charles River Laboratories Intl. by 11.9% in the 1st quarter. Allianz Asset Management GmbH now owns 239,646 shares of the medical research company’s stock valued at $25,579,000 after purchasing an additional 25,571 shares during the last quarter. Amalgamated Bank boosted its stake in shares of Charles River Laboratories Intl. by 6.5% in the 1st quarter. Amalgamated Bank now owns 10,547 shares of the medical research company’s stock valued at $1,126,000 after purchasing an additional 642 shares during the last quarter. Principal Financial Group Inc. boosted its stake in shares of Charles River Laboratories Intl. by 2.6% in the 1st quarter. Principal Financial Group Inc. now owns 207,753 shares of the medical research company’s stock valued at $22,176,000 after purchasing an additional 5,293 shares during the last quarter. WINTON GROUP Ltd boosted its stake in shares of Charles River Laboratories Intl. by 1.7% in the 1st quarter. WINTON GROUP Ltd now owns 57,049 shares of the medical research company’s stock valued at $6,089,000 after purchasing an additional 940 shares during the last quarter. Finally, Wesbanco Bank Inc. bought a new stake in shares of Charles River Laboratories Intl. in the 1st quarter valued at $1,327,000. 97.76% of the stock is currently owned by institutional investors.

Charles River Laboratories Intl. traded down $0.81, reaching $105.68, during trading on Friday, Marketbeat.com reports. 218,600 shares of the company were exchanged, compared to its average volume of 386,525. The stock has a market cap of $5.11 billion, a price-to-earnings ratio of 20.23, a P/E/G ratio of 1.35 and a beta of 0.69. Charles River Laboratories Intl. has a twelve month low of $91.33 and a twelve month high of $119.05. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.07 and a quick ratio of 1.78.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Get a free copy of the Zacks research report on Charles River Laboratories Intl. (CRL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply